Sanofi (SNY) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $112.71B, a trailing price-to-earnings ratio of 9.1 and a free-cash-flow yield of 7.0%. Over the most recent reported fiscal year, revenue grew 5.5% and free cash flow per share grew 21.6%. Nama's AI scorecard rates it Buy, 6.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Buy · 6.8/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Trailing · -18.8% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-21.8%
How far the last close sits under the highest price of the past five years.
Market cap
$112.71B
Trailing P/E
9.1
Price / book
0.7
Price / sales
2.0
FCF yield
7.0%
Dividend yield
5.1%
Gross margin
72.8%
Operating margin
20.6%
Net margin
8.1%
Revenue growth (YoY)
+5.5%
Revenue growth (3-yr annual)
+4.8%
EPS growth (YoY)
+10.2%
FCF/share growth (YoY)
+21.6%
Beta
0.3
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers General
SNY earnings
Next report: Jan 28, 2027 (Q4 2026, EPS estimate $0.87).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 30, 2026
$1.98
$1.51
+31.1%
$17.04B
Q2 2026
Jul 30, 2026
$1.20
$1.14
+5.3%
$13.76B
Q1 2026
Apr 23, 2026
$1.10
$1.03
+6.8%
$12.58B
Q4 2025
Jan 29, 2026
$0.91
$0.85
+7.1%
$13.65B
SNY analyst price target
Median target $54.50 from 9 analysts, ranging $44.00 – $63.00.
Nama's AI scorecard currently rates Sanofi Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SNY's P/E ratio?
Sanofi trades at a trailing price-to-earnings ratio of 9.1.
When does SNY report earnings?
Sanofi's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $0.87.
What is the SNY price target?
The median analyst price target from 9 analysts is $54.50, with a range of $44.00 – $63.00.
Is SNY Shariah compliant?
Nama's AAOIFI-style screen reads Sanofi as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.